参考文献/References:
[1] 国家心血管病中心,中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2023概要[J].中国循环杂志,2024,39(7):625-660.
[2] Kong P,Cui ZY,Huang XF,et al. Inflammation and atherosclerosis :signaling pathways and therapeutic intervention[J]. Signal Transduct Target Ther,2022,7(1):131.
[3] Fan J,Watanabe T. Atherosclerosis:known and unknown[J]. Pathol Int,2022,72(3):151-160.
[4] Witkowski M,Weeks TL,Hazen SL. Gut microbiota and cardiovascular disease[J]. Circ Res,2020,127(4):553-570.
[5] Jansen VL,Gerdes VE,Middeldorp S,et al. Gut?microbiota?and their metabolites in cardiovascular disease[J]. Best Pract Res Clin Endocrinol Metab ,2021,35(3):101492.
[6] Thomas MS,Fernandez ML. Trimethylamine?N-oxide?(TMAO),diet and?cardiovascular?disease[J]. Curr Atheroscler Rep,2021,23(4):12.
[7] Lemaitre RN,Jensen PN,Wang Z,et al. Plasma trimethylamine-N-oxide and incident ischemic stroke:the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis[J]. J Am Heart Assoc,2023,12(16):e8711.
[8] Tang WHW,Li XS,Wu Y,et al. Plasma trimethylamine N-oxide(TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study[J]. Am Heart J,2021,236:80-86.
[9] Heianza Y,Ma W,DiDonato JA,et al. Long-term changes in gut microbial metabolite trimethylamine N-oxide and coronary heart disease risk[J]. J Am Coll Cardiol,2020,75(7):763-772.
[10] Kong W,Ma J,Lin Y,et al. Positive association of plasma trimethylamine-N-oxide and atherosclerosis in patient with acute coronary syndrome[J]. Cardiovasc Ther,2022,2022:2484018.
[11] Amrein M,Li XS,Walter J,et al. Gut microbiota-dependent metabolite trimethylamine N-oxide(TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease(fCAD)[J]. Clin Res Cardiol,2022,111(6):692-704.
[12] Farhangi MA. Gut microbiota-dependent trimethylamine N-oxide and all-cause mortality:findings from an updated systematic review and meta-analysis[J]. Nutrition,2020,78:110856.
[13] Sun X,Jiao X,Ma Y,et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome[J]. Biochem Biophys Res Commun,2016,481(1-2):63-70
[14] Seldin MM,Meng Y,Qi H,et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB[J]. J Am Heart Assoc,2016,5(2):e002767.
[15] Liu Y,Dai M. Trimethylamine N-oxide generated by the gut microbiota is associated with vascular inflammation:new insights into atherosclerosis[J]. Mediators Inflamm,2020,2020:4634172.
[16] Chen H,Li J,Li N,et al. Increased circulating trimethylamine N-oxide plays a contributory role in the development of endothelial dysfunction and hypertension in the RUPP rat model of preeclampsia [J]. Hypertens Pregnancy,2019,38:96-104.
[17] Ma G,Pan B,Chen Y,et al. Trimethylamine N-oxide in atherogenesis:impairing endothelial self-repair capacity and enhancing monocyte adhesion [J]. Biosci Rep,2017,37:BSR20160244.
[18] Wang Z,Klipfell E,Bennett BJ,et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature,2011,472:57-63.
[19] Geng J,Yang C,Wang B,et al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway[J]. Biomed Pharmacother,2018,97:941-947.
[20] Luo Z,Yu X,Wang C,et al. Trimethylamine N-oxide promotes oxidative stress and lipid accumulation in macrophage foam cells via the Nrf2/ABCA1 pathway[J]. J Physiol Biochem,2024,80(1):67-79.
[21] Mohammadi A,Najar AG,Yaghoobi MM,et al. Trimethylamine-N-oxide treatment induces changes in the ATP-binding cassette transporter A1 and scavenger receptor A1 in murine macrophage J774A.1 cells[J]. Inflammation,2016,39(1):393-404.
[22] Zhu W,Gregory JC,Org E,et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk [J]. Cell,2016,165(1):111-124.
[23] Fu Q,Zhao M,Wang D,et al. Coronary plaque characterization assessed by optical coherence tomography and plasma trimethylamine-N-oxide levels in patients with coronary artery disease[J]. Am J Cardiol,2016,118(9):1311-1315.
[24] Pop D,D?d?rlat-Pop A,Tomoaia R,et al. Updates on the renin-angiotensin-aldosterone system and the cardiovascular continuum[J]. Biomedicines,2024,12(7):1582.
[25] Silva GM,Fran?a-Falc?o MS,Calzerra NTM,et al. Role of renin-angiotensin system components in atherosclerosis :focus on Ang-Ⅱ,ACE2,and Ang-1-7[J]. Front Physiol,2020,11:1067.
[26] Konop M,Radkowski M,Grochowska M,et al. Enalapril decreases rat plasma concentration of TMAO,a gut bacteria-derived cardiovascular marker [J]. Biomarkers,2018,23(4):380-385.
[27] Ufnal M,Jazwiec R,Dadlez M,et al. Trimethylamine-N-oxide:a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensinⅡin rats[J]. Can J Cardiol,2014,30(12):1700-1705.
[28] Jiang S,Shui Y,Cui Y,et al. Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin Ⅱ-induced hypertension[J]. Redox Biol,2021,46:102115.
[29] Nickenig G,Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis:part Ⅰ:oxidative stress and atherogenesis[J]. Circulation,2002,105(3):393-396.
[30] Wang Z,Wu F,Zhou Q,et al. Berberine improves vascular dysfunction by inhibiting trimethylamine-N-oxideviaregulating the gut microbiota in angiotensin Ⅱ-induced hypertensive mice[J]. Front Microbiol,2022,13:814855.
[31] 李天翔,李素娟,郝祥宇,等. 替米沙坦在动脉粥样硬化中对肠道菌群及其代谢产物TMAO的影响[J]. 中国临床药理学与治疗学,2020,25(11):1233-1241.
[32] 李天翔,李素娟,郝翔宇,等. 血管紧张素Ⅱ1型受体在氧化三甲胺促进ApoE~(-/-)小鼠动脉粥样硬化中的作用[J]. 中国现代医学杂志,2024,34(1):34-43.
[33] Unal H,Karnik SS. Constitutive activity in the angiotensinⅡtype 1 receptor:discovery and applications[J]. Adv Pharmacol,2014,70:155-174.
[34] Gao F,Bai R,Qin W,et al. AngiotensinⅡinduces the expression of periostin to promote foam cell formation in oxLDL-treated macrophages[J]. Int J Cardiol,2022,347:46-53.
[35] St Paul A,Corbett CB,Okune R,et al. AngiotensinⅡ,hypercholesterolemia,and vascular smooth muscle cells:a perfect trio for vascular pathology[J]. Int J Mol Sci,2020,21(12):4525.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(5):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(5):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(5):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(5):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[11]李轶男 裴汉军.氧化三甲胺促进动脉粥样硬化的研究进展[J].心血管病学进展,2022,(6):542.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.016]
LI Yinan,PEI Hanjun.Trimethylamine N-Oxide Promoting Atherosclerosis[J].Advances in Cardiovascular Diseases,2022,(5):542.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.016]
[12]赵海燕 关秀茹.NLRP3炎症小体介导氧化三甲胺加速动脉粥样硬化的新进展[J].心血管病学进展,2023,(11):1028.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023.11. 000]
ZHAO Haiyan,GUAN Xiuru.NLRP3 Inflammasome in Mediating Trimethylamine?Oxide Accelerates Atherosclerosis[J].Advances in Cardiovascular Diseases,2023,(5):1028.[doi:10. 16806/j. cnki. issn. 1004-3934. 2023.11. 000]